EVOQ Therapeutics in Ann Arbor today announced the advancement of its ongoing license and collaboration agreement with Amgen for the discovery and development of novel therapeutics.
The work will include the receipt of a milestone payment and expansion of the scope of collaboration to include a total of three indications in autoimmune disorders.
Amgen and EVOQ Therapeutics are collaborating on preclinical development of novel drugs using EVOQ’s NanoDisc platform. Amgen is responsible for clinical development and commercialization of the resulting products.
EVOQ Therapeutics granted Amgen exclusive rights to selected autoimmune programs and received an upfront payment along with milestone payments potentially totaling more than $240 million, in addition to royalties on sales of resulting therapies.
Amgen is a leader in inflammation with an innovative and biosimilar portfolio that includes approved and investigational products for a range of autoimmune diseases.
“We are very pleased to have achieved this important milestone in our collaboration with Amgen and we are excited to be moving each of the programs forward with our partner,” says David Giljohann, CEO at EVOQ Therapeutics.
